Horizon Therapeutics PLC (NASDAQ:HZNP) Receives Average Rating of “Buy” from Brokerages

Horizon Therapeutics PLC (NASDAQ:HZNP) has earned an average recommendation of “Buy” from the fifteen ratings firms that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, three have issued a hold rating and ten have assigned a buy rating to the company. The average 12-month target price among brokers that have covered the stock in the last year is $31.91.

A number of research firms recently issued reports on HZNP. Piper Jaffray Companies set a $33.00 target price on Horizon Therapeutics and gave the stock a “buy” rating in a research note on Thursday, April 4th. Jefferies Financial Group increased their target price on Horizon Therapeutics to $34.00 and gave the stock a “buy” rating in a research note on Friday, March 1st. Cantor Fitzgerald increased their target price on Horizon Therapeutics from $26.00 to $32.00 and gave the stock a “buy” rating in a research note on Tuesday, April 2nd. Mizuho set a $27.00 target price on Horizon Therapeutics and gave the stock a “hold” rating in a research note on Wednesday, May 8th. Finally, BMO Capital Markets increased their target price on Horizon Therapeutics to $29.00 and gave the stock a “market perform” rating in a research note on Thursday, April 4th. They noted that the move was a valuation call.

NASDAQ HZNP opened at $24.06 on Friday. The business’s 50 day simple moving average is $24.63. Horizon Therapeutics has a 52-week low of $16.11 and a 52-week high of $29.44. The company has a debt-to-equity ratio of 0.90, a current ratio of 1.74 and a quick ratio of 1.68.

Horizon Therapeutics (NASDAQ:HZNP) last posted its earnings results on Wednesday, May 8th. The biopharmaceutical company reported $0.30 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.10 by $0.20. Horizon Therapeutics had a return on equity of 33.57% and a net margin of 3.79%. The business had revenue of $280.00 million during the quarter, compared to analysts’ expectations of $238.35 million. During the same period in the prior year, the business earned $0.03 EPS. Horizon Therapeutics’s revenue for the quarter was up 25.0% compared to the same quarter last year. As a group, sell-side analysts expect that Horizon Therapeutics will post 1.62 earnings per share for the current year.

In other Horizon Therapeutics news, insider Jeff Kent sold 3,620 shares of the company’s stock in a transaction that occurred on Wednesday, June 5th. The stock was sold at an average price of $24.64, for a total transaction of $89,196.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 4.10% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in HZNP. Daiwa Securities Group Inc. acquired a new stake in shares of Horizon Therapeutics in the 1st quarter valued at approximately $29,000. Manchester Capital Management LLC acquired a new stake in shares of Horizon Therapeutics in the 1st quarter valued at approximately $41,000. Quadrant Capital Group LLC acquired a new stake in shares of Horizon Therapeutics in the 1st quarter valued at approximately $53,000. Quantamental Technologies LLC acquired a new stake in shares of Horizon Therapeutics in the 1st quarter valued at approximately $88,000. Finally, SG Americas Securities LLC boosted its holdings in shares of Horizon Therapeutics by 79.5% in the 4th quarter. SG Americas Securities LLC now owns 9,438 shares of the biopharmaceutical company’s stock valued at $184,000 after buying an additional 4,179 shares during the last quarter. 87.79% of the stock is owned by hedge funds and other institutional investors.

About Horizon Therapeutics

Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.

Featured Article: Why is the Consumer Price Index (CPI) important?

Analyst Recommendations for Horizon Therapeutics (NASDAQ:HZNP)

Receive News & Ratings for Horizon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.